Neurology & CNS patent intelligence

US 8394380

Compositions and methods for alzheimer's disease

Primex Clinical Laboratories, Inc. · Granted Tue Mar 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8389478

Methods and compositions for treating neurodegenerative disorders and Alzheimer's disease and improving normal memory

The Regents of the University of California · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8372826

Estriol therapy for multiple sclerosis and other autoimmune diseases

The Regents of the University of California · Granted Tue Feb 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8309355

Methods of treating Parkinson's disease using viral vectors

The Regents of the University of California · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8298525

Method of treating multiple sclerosis with interferon-beta and an IL-2R antagonist

The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8293800

Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 23 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 18 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8232373

Immunogenic peptide composition for the prevention and treatment of alzheimer's disease

United Biomedical, Inc. · Granted Tue Jul 31 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8153604

CNS-tumor treatment method and composition

The Regents of the University of California · Granted Tue Apr 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8129334

Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory

The Regents of the University of California · Granted Tue Mar 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8101380

Schizophrenia-related isoform of KCNH2 and development of antipsychotic drugs

The United States of America, as represented by the Secretary, Health and Human Services · Granted Tue Jan 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7968511

Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 28 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7922999

Administration of growth factors for the treatment of CNS disorders

The Regents of the University of California · Granted Tue Apr 12 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7879548

Detection of biomarkers for neuropsychiatric disorders

The Regents of the University of California · Granted Tue Feb 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7846892

Compositions and methods for Alzheimer's disease

Primex Clinical Laboratories, Inc. · Granted Tue Dec 07 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7829279

Compositions and methods for diagnosis and treatment of epilepsy

The Regents of the University of California · Granted Tue Nov 09 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7727957

Treatment and delay of outset of Parkinson's disease

The Regents of the University of California · Granted Tue Jun 01 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 27 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7622461

Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders

ACADIA Pharmaceuticals Inc. · Granted Tue Nov 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7619005

Methods for treating cognitive impairment in humans with Multiple Sclerosis

Cognition Pharmaceuticals, LLC · Granted Tue Nov 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7550454

Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders

ACADIA Pharmaceuticals Inc. · Granted Tue Jun 23 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 18 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7534613

Methods of treating parkinson's disease using viral vectors

The Regents of the University of California · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7517871

Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders

ACADIA Pharmaceuticals Inc. · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7491715

Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders

ACADIA Pharmaceuticals Inc. · Granted Tue Feb 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7479579

Triple transgenic mouse model of Alzheimer's disease

The Regents of the University of California · Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7470431

Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer

The Regents of the University of Colorado · Granted Tue Dec 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7465715

Method for treatment of multiple sclerosis

CAN-FITE BIOPHARMA LTD. · Granted Tue Dec 16 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 11 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7258859

Method for the treatment of multiple sclerosis

The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Aug 21 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

CA 2591889

TRAITEMENT DE LA DEPRESSION MELANCOLIQUE SEVERE A L'AIDE D'EPA

AMARIN NEUROSCIENCE LTD [GB] · Granted Thu Jun 29 2006 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 24 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

SI 1148873

HIGHLY PURIFIED ETHYL EPA AND OTHER EPA DERIVATIVES FOR NEUROLOGICAL DISORDERS

AMARIN NEUROSCIENCE LTD [GB] · Granted Sat Dec 31 2005 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Fri Dec 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6936599

Estriol therapy for multiple sclerosis and other autoimmune diseases

The Regents of the University of California · Granted Tue Aug 30 2005 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6894026

Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders

Atossa Healthcare, Inc. · Granted Tue May 17 2005 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6762032

Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response

BioCrystal, Ltd. · Granted Tue Jul 13 2004 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6740638

Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Neurocrine Biosciences, Inc. · Granted Tue May 25 2004 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6737059

Methods of inhibiting inflammatory processes and alleviating symptoms associated with multiple sclerosis

The Board of Regents of the University of Washington · Granted Tue May 18 2004 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6673332

Assays for inhibitors of neuronal transport of Alzheimer's amyloid precursor protein

The Regents of the University of California · Granted Tue Jan 06 2004 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6656930

Aralkyl diazabicycloalkane derivatives for CNS disorders

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Dec 02 2003 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6489299

Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Neurocrine Biosciences, Inc. · Granted Tue Dec 03 2002 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6410747

Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Jun 25 2002 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6379670

Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein

Neurocrine Biosciences, Inc. · Granted Tue Apr 30 2002 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6369033

Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Neurocrine Biosciences, Inc. · Granted Tue Apr 09 2002 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6350479

Treating depression with alcohol extracts of tobacco

Regent Court Technologies, LLC · Granted Tue Feb 26 2002 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6329499

Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein

Neurocrine Biosciences, Inc. · Granted Tue Dec 11 2001 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

EP 1148873

HOCHREINES ETHYLEICOSAPENTAENAT UND ANDERE EPA-DERIVATE ZUR BEHANDLUNG VON NEUROLOGISCHEN ERKRANKUNGEN

LAXDALE LTD [GB] · Granted Wed Oct 31 2001 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6309634

Methods of treating Parkinson's disease using recombinant adeno-associated vector (rAAV)

The Regents of the University of California · Granted Tue Oct 30 2001 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6310064

Aralkyl diazabicycloalkane derivatives for CNS disorders

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Oct 30 2001 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6251396

Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein

Neurocrine Biosciences, Inc. · Granted Tue Jun 26 2001 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6248528

Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders

The Regents of the University of California · Granted Tue Jun 19 2001 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6166008

Treatment of schizophrenia with ampakines and neuroleptics

The Regents of the University of California · Granted Tue Dec 26 2000 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6127598

NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity

The Regents of the University of California · Granted Tue Oct 03 2000 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time)